bluuebunny/crossref_metadata_2025_split huggingface dataset:
Coexpression of p165 myeloid surface antigen and terminal deoxynucleotidyl transferase: A comparison of acute myeloid leukaemia and normal bone marrow cells
Authors: Bradstock Kenneth F. , Kerr Arna , Kabral Arnold , Favaloro Emmanuel J. , Hewson John W. 
Published: February 2007

AbstractA double immunofluorescence technique, using antibodies to terminal transferase (TdT) and a 165‐kilodalton myeloid differentiation antigen (p165), has been used to investigate the phenomenon of TdT expression in cases of acute myeloid leukaemia (AML). Five cases of AML were shown to have significant (18‐90%) numbers of leukaemic cells that concurrently expressed both TdT and p165 myeloid surface antigen. Examination of nonleukaemic bone marrow cells showed that the vast majority of normal TdT+ cells are p165 negative. However, in 5 of the 11 samples analyzed, rare cells staining for both p165 and TdT were found. These results suggest that some cases of TdT + AML may arise from the clonal expansion of rare “biphenotypic” precursor cells existing in normal bone marrow.
Quantitation of the monoclonal plasma cell component in bone marrow from patients with serum paraproteinemia and nondiagnostic marrow morphology
Authors: Gordon Vanessa , Bezwoda Werner , Derman Dennis , Kramer Sydney , Mendelow Barry 
Published: February 2007

AbstractTwenty‐one patients with serum monoclonal gammopathy but lacking acceptable morphological evidence of myelomatosis were studied with reference to the degree, if any, of monoclonal plasma cell expansion in aspirated marrow samples, enriched for plasma cells and analysed with respect to light chain distribution. Four of these patients had a biopsy‐proven plasmacytoma of bone. Bone marrow aspirated from sites distant to the tumor showed clear evidence of infiltration by monoclonal plasma cells in two of the cases studied; the other two patients had normal results. Of the 17 other cases, 14 showed evidence of a monoclonal plasma cell component qualitatively concordant with the serum paraprotein as one would expect. These cases could be subdivided into those with myeloma (six cases) and those with monoclonal gammopathy of undetermined significance (eight cases) on the basis of conventional biochemical and radiological criteria. Three of the 17 patients, however, did not show evidence of monoclonal plasma cell infiltration, despite the presence of lytic lesions. It is important to recognize this minority group that simulates myeloma but that may well reflect alternative pathology that has not been identified.
Microcytosis in Hodgkin disease associated with unbalanced globin chain synthesis
Authors: Fahey John L. , Rahbar Samuel , Farbstein Mark J. , Forman Stephen J. , Blume Karl G. , Beutler Ernest 
Published: February 2007

AbstractA review of 162 patients with Hodgkin disease disclosed 36 with microcytic anemia (mean corpuscular hemaglobin values [MCV] <80 fl). Three patients had iron deficiency, and one had β‐thalassemia. Of the remaining 32 patients, 24 had microcytic anemia at the time of diagnosis of Hodgkin disease, and ten, including two patients with this finding initially, developed microcytic anemia in association with recurrence of Hodgkin disease. Seven patients with Hodgkin disease and normal MCV had normal α‐to‐β‐globin chain ratios (1.0 ± 0.14). Seven patients with Hodgkin disease and MCV <80 fl had significantly lower α‐to‐β chain ratios (0.66 ± 0.05). Twelve normal controls and four with iron‐deficiency anemia and MCV <80 fl had normal ratios. Anemia was corrected, and MCV returned to normal in all patients who responded to therapy for Hodgkin disease. In the two patients studied sequentially, abnormal α‐to‐β‐chain ratio was corrected along with the anemia.
High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study
Authors: Preisler H. D. , Raza A. , Barcos M. , Azarnia N. , Larson R. , Browman G. , Walker I. , Grunwald H. , D'Arrigo P. , Stein A. , Bloom M. , Goldberg J. , Gottlieb A. , Bennett J. , Kirshner J. , Priore R. 
Published: February 2007

AbstractFifteen patients with myelodysplastic/myeloproliferative disorders were treated with high‐dose cytosine arabinoside therapy. While severe toxicity was produced in every patient, only two of the 15 patients entered complete remission and two achieved partial remission status. The therapeutic responses were confined to patients who had severe myelofibrosis of apparently recent onset.
Pyruvate kinase deficiency in dog and human erythrocytes: Effects of energy depletion on cation composition and cellular hydration
Authors: Muller‐Soyano Aixa , Platt Orah , Glader Bertil E. 
Published: February 2007

AbstractPyruvate kinase‐ (PK) deficient human reticulocytes incubated 4 hr under conditions where mitochondrial oxidative phosphorylation is inhibited become ATP‐depleted. Concomitantly, these energy‐depeleted red blood cells (RBC) lose massive amounts of potassium and water. PK‐deficient reticulocyte‐rich RBC from a Basenji dog, incubated under the same conditions, also manifest ATP‐depletion and K‐loss. In contrast to the cation changes in human cells, however, K‐loss in PK‐deficient dog reticulocyte‐rich RBC is balanced by an equivalent Na gain, and consequently these canine erythrocytes do not undergo any change in cellular hydration, Potassium depletion and dehydration, which may be related to membrane injury in human RBC, do not appear to be involved in the hemolysis of PK‐deficient dog erythrocytes.
Eosinophilic fibrohistiocytic lesion of bone marrow associated with monoclonal gammopathy and osteolytic lesions
Authors: Nagler A. , Ben‐Arieh Y. , Brenner B. , Tatarsky I. , Pollack S. 
Published: February 2007

AbstractWe describe a 63‐year‐old male patient with severe osteoporosis, multiple lytic bone lesions, and monoclonal gammopathy (IgGλ). Whereas the tentative diagnosis in this case was multiple myeloma, bone marrow trephine biopsies of the iliac crest and from an osteolytic lesion of the tibia both showed a peculiar infiltrate consisting of numcrous clongated mast cells, eosinophils, and some plasma cells and lymphocytes. The bone marrow lesions fit the diagnosis of eosinophilic fibrohistiocytic lesion of bone marrow (EFHBM). The patient had no abnormality that could be related to a known allcrgic disease, and no relationship to drug hypersensitivity could be established. The features of the bone marrow infiltrate and its association with monoclonal gammopathy may suggest a linkage between EFHBM and the monoclonal gammopathy.
The mechanisms of sulfonylurea‐induced immune hemolysis: Case report and review of the literature
Authors: Kopicky Joyce A. , Packman Charles H. 
Published: February 2007

AbstractChlorpropamide, a sulfonylurea antidiabetic drug, was found to be the etiologic agent in a patient with immune hemolytic anemia. Hemolysis was severe, and ceased promptly when the drug was discontinued. The direct antiglobulin test was positive for complement, and the indirect antiglobulin test was also positive when the drug, patient serum, and fresh serum complement were all present. In this patient, and in four other patients described in the literature, hemolysis was mediated by the immune complex mechanism. In reports of two other patients taking a sulfonylurea drug, a milder form of hemolysis was mediated by the hapten mechanism. Sulfonylurea drugs are widely used. Since immune complex‐mediated hemolysis in these patients is dramatic, it is not likely to be missed. However, the slower, milder hemolysis mediated by the hapten mechanism may be more common than is realized. Such patients may have only mild anemia and a near‐normal reticulocyte count, making the diagnosis difficult. It is thus important to consider drug‐immune hemolysis in patients who become anemic while taking sulfonylurea drugs.
Hepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti‐LAV/HTLV‐III‐positive patients
Authors: Zanetti A. R. , Mannucci P. M. , Tanzi E. , Moroni G. A. , De Paschale M. , Morfini M. , Carnelli V. , Tirindelli M. C. , De Biasi R. , Ciavarella N. , De Rosa V. , Rodeghiero F. , Colombo M. 
Published: February 2007

AbstractOne‐hundred thirteen adults and children with hemophilia or other congenital bleeding disorders were vaccinated against the hepatitis B virus. Each patient was given three subcutaneous injections of the vaccine at monthly intervals and then a fourth booster dose 14 months after the first. The vaccine was highly immunogenic, since 111 of 113 patients (98%) produced anti‐HBs (10 mlU/ml or more). After the first three vaccine doses and after the booster dose, ten anti‐LAV/HTLV‐III‐positive hemophiliacs produced anti‐HBs but had a lower average titer than anti‐LAV/HTLV‐III‐negative hemophiliacs. Of the 23 patients treated with concentrates in the 15 month postvaccination period only, none acquired HBV infection. Of the 50 patients treated with concentrates also in the 6 month prevaccination period, one developed hepatitis B. In summary, the vaccine was highly immunogenic in both children and adults with hemophilia; anti‐LAV/HTLV‐III‐positive patients responded to the vaccine, but the average anti‐HBs response was lower; no case of hepatitis B occurred in patients treated with concentrates only in the postvaccination period.
Megakaryocytic colony formation (CFU‐Meg) in essential thrombocythemia: Quantitative and qualitative abnormalities of bone marrow CFU‐Meg
Authors: Klmura Hideo , Ishibashi Toshiyuki , Sato Tadashi , Matsuda Shin , Uchida Tatsumi , Kariyone Shigeo 
Published: February 2007

AbstractFor the purpose of examining the mechanisms for the overproduction of megakaryocytes and platelets in essential thrombocythemia (ET), marrow megakaryocytic colony‐forming units (CFU‐Meg) were characterized using a methylcellulose culture system in nine patients with ET, and they were compared with those of 16 control subjects and four patients with secondary thrombocytosis (ST). The number of CFUMeg per 105 cells in ET was significantly higher (p< 0.001) than that in the controls (5.8 times of the controls) or that in ST. ET showed endogenous CFU‐Meg (58 ± 16% of the total CFU‐Meg) that could form megakaryocytic colonies without phytohemagglutinin‐stimulated leukocyte‐conditioned medium (PHA‐LCM) as a source of Meg‐CSA. The controls and the patients with ST revealed no endogenous CFU‐Meg. The dose‐response studies with PHA‐LCM revealed that CFU‐Meg from ET are highly sensitive to low concentrations of PHA‐LCM compared to CFU‐Meg from the control and ST.Erythropoietic burst‐forming units (BFU‐E) were monitored as a control progenitor, because the patients with ET studied did not have erythrocytosis. Although five out of nine patients with ET had endogenous BFU‐E, the percentages of endogenous BFU‐E were small (4–10%). The number of BFU‐E in ET was not different from the control value. Thus, ET is associated with an enlarged CFU‐Meg compartment that shows abnormal growth patterns when cultured in vitro, while the growth abnormality of BFU‐E is small, which may underlie the hematological features of ET. The culture of CFU‐Meg should be clinically useful for differentiating ET from ST.
Analysis of cell cycle characteristics and course of the disease in ANLL
Authors: Raza Azra , Maheshwari Yogesh , Brereton William , Preisler Harvey D. 
Published: February 2007

AbstractThe cell cycle characteristics of a newly diagnosed patient with acute nonlymphocytic leukemia (ANLL) were studied by using intravenous bromodeoxyuridine (BrdU) and our previously described “double‐label” technique. The percentage of S‐phase cells in the bone marrow (BM) biopsy were 25 % compared to 7 % from the simultaneously obtained BM aspirate. The duration of S‐phase (Ts) was determined to be 4 hr and the total cell cycle time (Tc) was 16 hr. We demonstrated that the actual clinical course of this patient's illness corresponded well with the course predicted on the basis of these cell cycle measurements. Although he achieved aplasia in response to two successive courses of induction chemotherapy, leukemic cells repopulated the marrow, producing a rapidly rising PB white blood cell (WBC) count with a T1/2 of approximately 20 hr each time. It is likely that the resistance of this patient's leukemia to therapy was a result of the rapid proliferative rate of his leukemic cells and not due to the inability of chemotherapeutic agents to kill a large number of cells. Since the measurements can be completed within 48 hr, measuring Ts and Tc will provide a better understanding of the biological differences that exist between patients with ANLL.
Peripheral blood t‐cell subpopulations in the very low birth weight (less than 1,500‐g) infant
Authors: Ballow Mark , Cates K. Lynn , Rowe Jonelle C. , Goetz Cynthia , Pantschenko Alexander G. 
Published: February 2007

AbstractThe development of monoclonal antibodies to cell‐surface antigens has provided method for characterizing distinct subpopulations of T‐cells. In the present study we have quantified peripheral blood T‐cell subpopulations in premature infants born weighing less than 1,500 g (1123 ± 223 g) and ranging in gestational age from 25 to 32 weeks. The relative proportion of T4 cells in the very low birth weight (VLBW) infants was markedly higher at l week and 1 month of age (mean ± SEM; 67.5 ± 4.1 and 59.2 ± 1.6) than in adult controls (47.2 ± 1.5). The percentage of T4 cells remained elevated until 6 months of age, when it decreased to a level comparable to that in adults. In contrast, the proportion of T8 cells was significantly lower than the adult level at 1 week and 1 month of age. The T4/T8 ratio in the VLBW infants was higher at 1 week (4.3 ± 0.5) and 1 month (3.5 ± 0.2) than in adult controls (2.0 ± 0.1). Thereafter, the T4/T8 ratio decreased but was still significantly higher than that in adult controls at 6 months of age (2.6 ± 0.2). The absolute numbers of total T‐cells (T3) and T8 and T4 cells were significantly higher in VLBW infants. The numbers of T8 cells were significantly lower in the first month of life than at 3‐6 months of age. These alterations in the T‐cell subsets in the first 6 months of life suggest that postnatal T‐cell phenotypic changes in VLBW infants may parallel the T‐cell ontogenetic process which occurs during the last trimester of pregnancy in fullterm infants.
Iron status of beta thalassemia carriers
Authors: Mehta B. C. , Pandya B. G. 
Published: February 2007

AbstractOne hundred twenty‐four relatives (aged 17‐52 years) of 35 children with severe transfusion‐dependent beta thalassemia major were investigated for their beta thalassemia carrier status (determined by Hb‐A2 level) and iron status (determined by serum ferritin level). Forty‐eight males had beta thalassemia trait (BTT) and 18 males did not have BTT (control); 41 females had BTT and 17 females did not have BTT (control). Serum ferritin levels (mean ± SEM) of male BTT, male control, female BTT, and female control groups were 151.0 ± 27.4, 59.6 ± 16.3, 120.6 ± 36.6, and 17.2 ± 6.1 meg/liter respectively; the differences between the two male and the two female groups were statistically significant (p = 0.05 and p < 0.001). Iron deficiency (serum ferritin below 10.0 meg/liter) was present in 6.3%, 38.9%, 24.4%, and 58.8% of male BTT, male control Female BTT, and female control groups, respectively; the differences between the two male and two female groups were statistically significant (p < 0.01 and p < 0.01). Serum ferritin was over 1,000 meg/liter in four individuals with BTT (2 male and 2 female). Thus, the BTT group had better iron nutrition. This may suggest that the BTT group has an advantage in maintaining iron balance.
Case report: T‐cell acute lymphoblastic leukemia relapsing as acute myelomonocytic leukemia and terminating possibly as chronic myelocytic leukemia
Authors: Shimizu Jyoji , Hamashima Yoshihiro , Tsuda Hideo , Akiyama Yuichi , Mikawa Haruki , Ikehara Susumu 
Published: February 2007

AbstractA 9‐year‐old boy suffering from T‐cell acute lymphoblastic leukemia (T‐ALL) with a mediastinal mass had a complete remission as a result of treatment. Ten months later, he developed a typical acute myelomonocytic leukemia (AMMoL) pattern. Two months after a second relapse, he showed a clinical picture that was indistinguishable from chronic myelocytic leukemia (CML).At autopsy, massive infiltration of CML‐like cells was observed even in the thymus (190 g). These observations suggest that the leukemia in this child arose in a pluripotent stem cell capable of differentiation into both T‐lymphocytic and myelomonocytic lineages.
An autoantibody with poten antithrombin activity whose action could be inhibited by toluidine blue or methylene blue
Authors: Shojania A. Majid , Meilleur Gisele , Alvi Abdul W. 
Published: February 2007

AbstractA 41‐year‐old man with posthepatitic liver cirrhosis and bleeding tendency was found to have a circulating anticoagulant with potent antithrombin activity. The thrombin time of the patient's purified fibrinogen was normal. This anticoagulant was residing in the patient's IgG fraction, and his IgG fraction could prolong the thrombin time of purified fibrinogen, suggesting that this circulating anticoagulant was an antibody. No heparin was detected in the patient's plasma. However, the antithrombin activity of this anticoagulant could be neutralized by toluidine blue or methylene blue ex vivo.
Restoration of decreased suppressor cells by vitamin B12therapy in a patient with pernicious anemia
Authors: Kubota Kazuo , Arai Toshimasa , Tamura Jun'Ichi , Shirakura Takuo , Morita Toyoho 
Published: February 2007

AbstractA unique case of pernicious anemia is described. Initially, the percentage of OKT8‐positive blood cells was markedly decreased, resulting in an increase in the OKT4/OKT8 ratio. The level of OKT8‐positive blood cells was, however, returned to normal after vitamin B12therapy. The finding may propose a possible role of the imbalance of blood lymphocyte subpopulations on the pathogenesis of pernicious anemia and also a responsibility of vitamin B12for such a selective reduction in the OKT8‐positive blood cells.
Transient response of pure red cell aplasia to anti‐thymocyte globulin in a patient with T‐cell chronic lymphocytic leukemia
Authors: Hocking William , Champlin Richard , Mitsuyasu Ronald 
Published: February 2007

AbstractPure red cell aplasia (PRCA) is an unusual complication of chronic lymphoproliferative disorders. A patient with T‐cell chronic lymphocytic leukemia (T‐CLL) had severe anemia and neutropenia. Initial in vitro studies demonstrated no evidence of T‐cell suppression of erythropoiesis. Sequential bone marrow examinations demonstrated progressive red cell aplasia. In vitro studies showed that the T‐cells from the patient suppressed allogeneic but not autologous BFU‐E. Treatment with antithymocyte globulin (ATG) reduced circulating leukemic cells and produced a definite but transient improvement in erythropoiesis.
Marked hypodiploidy in blast phase chronic myelogenous leukemia: Report of a case and review of the literature
Authors: Cibull Michael L. , Thompson Mark E. , Smith Linda , Jennings C. Darrell , Doukas Michael A. , Pavlik Edward J. , Powell Deborah E. 
Published: February 2007

AbstractThe emergence of a near‐haploid clone of cells in blast phase chronic myelogenous leukemia is an unusual event. We report such a case and review eight other cases described in the English literature. The significance of the substantial loss of genetic material is discussed as is the phenotypic and genotypic heterogeneity observed in this group of patients.
Two new variants of glucose‐6‐phosphate dehydrogenase associated with hereditary non‐spherocytic hemolytic anemia: G6PD wayne and G6PD huron
Authors: Ravindranath Y. , Beutler Ernest 
Published: February 2007

AbstractTwo new deficient variants of glucose‐6‐phosphate dehydrogenase (G6PD) causing hereditary nonspherocytic hemolytic anemia (HNSHA) are described. Both of these are unique and they have been named G6PD Wayne and G6PD Huron. Patients with G6PD Wayne underwent splenectomy and no objective improvement was noted. The patients with G6PD Huron were under medical observation for a considerable period of time without the diagnosis of G6PD deficiency being entertained because the family was of Northern European origin. Since sporadic variants of G6PD causing HNSHA show no special racial predilection, the diagnosis of G6PD deficiency should always be considered in patients with this syndrome.
Use of capillary blood for the evaluation of iron status
Authors: Lu Yuying , Lynch Sean R. , Cook James D. , Madan Nishi , Bayer William L. 
Published: February 2007

AbstractThe accuracy and precision of measurements of iron status made on the capillary blood from a single 75 × 1‐mm microhematocrit tube were evaluated in 301 normal volunteers. After recording the hematocrit value, a hematofluorometer was used to assay erythrocyte protoporphyrin directly on the packed red cell fraction. Values in the low normal range were 50‐100% higher than assays by an extraction technique in simultaneously collected venous blood. However, measurements in the iron deficient range were only 12 % greater. Plasma ferritin concentration was determined by using an enzyme‐linked immunoassay on 10‐μl plasma retrieved after measuring the hematocrit. Capillary values were approximately 7% higher than venous concentrations, the proportional difference being consistent throughout the measured range. When the individual measurements were combined to calculate the iron storage status of each individual, the frequency distribution of iron stores in 141 female volunteers between 18 and 36 years of age was approximately Gaussian and paralleled that calculated for women aged 18‐44 years in NHANES II. These studies demonstrate that iron status can be r'etermined accurately from the measurement of hematocrit, erythrocyte protoporphyrin, and ferritin on a single microhematocrit tube of capillary blood.
Predictive value of enzyme‐linked immunoassay platelet crossmatching for transfusion of platelet concentrates to alloimmunized recipients
Authors: Brubaker Daniel B. , Duke James C. , Romine Maxine 
Published: February 2007

AbstractSome evidence has shown that platelet crossmatching is useful in multitransfused patients with hypoplastic bone marrows who are refractory to platelet therapy through alloimmunization. Several immunoglobulin binding assays other than enzyme‐linked immunospecific assay (ELISA) have been studied previously. We performed 51 ELISA crossmatches on six patients receiving single donor platelets. One bone marrow transplant patient receiving 33 single donor HLA matched (related and unrelated) was also studied. Effectiveness of transfusion was closely monitored by patient evaluation and corrected platelet count increment (CCI) at 1‐2 and 18‐24 hours posttransfusion. We found the ELISA method very sensitive, specific, and predictive, 85, 96, and 95.6% respectively in the 51 crossmatches studied in six patients with either leukemia, solid tumors, or aplastic anemia. However, variation existed among individual recipients, with sensitivity ranging from 70‐100%. The distribution of true positives and negatives and false positives and negatives in the 33 crossmatches performed in the bone marrow transplant patient differed significantly (X2 − 101.2; P < 0.001) from single donor recipients. The specificity in the 51 crossmatches on the six patients was also significantly different from the 33 crossmatches performed in the bone marrow transplant (96 vs 74%). This suggests individual variation occurs as well as differences in diseases and bone marrow suppressive agents affecting platelet crossmatching.